Postmenopausal overweight and breast cancer risk; results from the KARMA cohort.
BMI
Breast cancer risk
Breast cancer subtypes
Obesity
Overweight
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
16
02
2022
accepted:
21
06
2022
pubmed:
31
8
2022
medline:
13
10
2022
entrez:
30
8
2022
Statut:
ppublish
Résumé
To study the risk of incident breast cancer and subtype-specific breast cancer in relation to excess body weight in a contemporary Swedish prospective cohort study, The Karolinska Mammography Project for Risk Prediction of Breast Cancer, KARMA. A total of 35,412 postmenopausal women attending mammography and included in the KARMA study provided baseline data on body mass index (BMI) and potential confounders. During eight years of follow-up, 822 incident invasive breast cancer cases were identified. Women with overweight (BMI ≥ 25-< 30 kg/m Overweight and obesity are associated with an increased risk of developing breast cancer, specifically ER+, low-grade, and for obesity, node-positive, high-risk breast cancer indicating a further need for risk communication and preventive programs.
Identifiants
pubmed: 36040641
doi: 10.1007/s10549-022-06664-7
pii: 10.1007/s10549-022-06664-7
pmc: PMC9550786
doi:
Substances chimiques
Receptors, Estrogen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
185-196Subventions
Organisme : Fru Berta Kamprads Stiftelse
ID : FBKS-2018-22 - (167)
Organisme : Governmental Funding of Clinical Research within the National Health Service
ID : 2018-Project 0211
Organisme : Märit and Hans Rausing Initiative Against Breast Cancer
ID : Personal donation
Informations de copyright
© 2022. The Author(s).
Références
J Natl Cancer Inst. 2020 Sep 1;112(9):929-937
pubmed: 31845728
Int J Obes Relat Metab Disord. 2002 Jun;26(6):747-53
pubmed: 12037643
Int J Epidemiol. 2019 Dec 1;48(6):1872-1885
pubmed: 31566221
J Clin Oncol. 2016 Dec 10;34(35):4270-4276
pubmed: 27903155
Breast Cancer Res Treat. 2013 Jan;137(1):307-14
pubmed: 23179600
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
Cancer Causes Control. 2019 Nov;30(11):1183-1200
pubmed: 31471762
Front Oncol. 2019 Sep 04;9:765
pubmed: 31555578
Cancer Epidemiol Biomarkers Prev. 2022 Feb;31(2):325-333
pubmed: 34782393
Eur J Epidemiol. 2021 Jan;36(1):37-55
pubmed: 33128203
BMJ. 2007 Dec 1;335(7630):1134
pubmed: 17986716
Front Endocrinol (Lausanne). 2018 Nov 22;9:689
pubmed: 30524378
Nutr Metab Cardiovasc Dis. 2010 Jan;20(1):41-8
pubmed: 19361966
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2078-86
pubmed: 18664548
Int J Epidemiol. 2022 Jan 6;50(6):1914-1926
pubmed: 34999853
Front Oncol. 2021 Mar 02;11:628653
pubmed: 33738261
CA Cancer J Clin. 2017 Sep;67(5):378-397
pubmed: 28763097
Arch Intern Med. 2007 Oct 22;167(19):2091-102
pubmed: 17954804
JAMA Oncol. 2015 Aug;1(5):611-21
pubmed: 26182172
Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1686-91
pubmed: 16030102
J Natl Cancer Inst. 2022 Mar 8;114(3):361-371
pubmed: 34021349
Int J Cancer. 2006 Oct 1;119(7):1683-9
pubmed: 16646051
Epidemiol Rev. 2014;36:114-36
pubmed: 24375928
Proc Nutr Soc. 2018 Nov;77(4):403-411
pubmed: 29478430
Int J Epidemiol. 2017 Dec 1;46(6):1740-1741g
pubmed: 28180256
Br J Cancer. 1987 Nov;56(5):661-6
pubmed: 3426933
Ann Surg. 2020 Dec;272(6):1053-1059
pubmed: 30998538
Int J Cancer. 2004 Sep 20;111(5):762-71
pubmed: 15252848
J Clin Oncol. 2016 Jan 20;34(3):251-8
pubmed: 26628467
Cancer. 1994 Aug 1;74(3 Suppl):1090-100
pubmed: 8039144